Scientific software is being purpose-built and adopted across all aspects of biopharma workflows. Biotech and
pharmaceutical organisations of all sizes and modalities, including small molecules, biologics and cell and gene
therapies, are rapidly embracing these digital solutions to transform research and development and accelerate
therapeutic discovery. While hardware innovations such as liquid-handling workstations, robotic sample movers, shakers and incubators might come to mind, equally critical is the role of software. For example, software helps manage growing sample numbers and data complexity from high-throughput workflows that process thousands of new samples in a single week. These laboratory modernisation efforts have driven major gains in efficiency and throughput, as reported in a recent survey of R&D executives who said 53% have already experienced increased laboratory throughput as a direct result of digital transformation initiatives. This is expected to rise to 85% by the end of 2028.1
Software not only orchestrates laboratory systems, but it is also crucial for managing data workflows. Automated and systematic data capture, parsing and analysis enable faster experimental testing, cross functional collaboration and regulatory ready reports. Well-governed datasets are also foundational for applying AI and advanced analytics in drug discovery. The drug discovery technologies market has grown to $30.58 billion and continues to expand.2 While this growth is accelerating therapeutic discovery, it also creates a complex landscape of software hosting and licensing models. So, choosing how to implement software and store data to deliver the most strategic value to your organisation is a challenge.
